ICPerMed is happy to inform you
that the European Partnership for Personalised
Medicine (EP PerMed) has now officially started.
Congratulations and we are looking forward to our
collaboration!
EP PerMed aims to improve future
healthcare for all citizens through personalised
therapy, diagnosis and prevention. With a total
budget of around €375 million, provided by the EU
and more than 50 international partners, EP PerMed
will not only significantly support the
transnational development of personalised medicine
approaches over the next ten years, but also their
successful translation into clinical practice. A
preliminary announcement for the first joint
transnational call for proposals (JTC2024) has now
been published on the EP PerMed
Website.
"The concept of personalised medicine combines
biomedical research and other disciplines with the
use of cutting-edge technologies. The resulting
increasing number of personalised therapies
enables us to better understand diseases and treat
them more precisely, while at the same time
reducing unwanted side effects," says Dr Wolfgang
Ballensiefen, who is responsible for coordinating
the partnership at the German Aerospace Center’s
project management agency, DLR Projektträger. "In
addition, personalised medicine aims at a specific
and early diagnosis of diseases, which enables
individualised prognoses and ultimately early and
targeted treatment or prevention."
The European
Partnership for Personalised Medicine brings
together ministries, funding organisations and
research infrastructures from 24 countries and 10
European regions. EP PerMed builds on the results
and experience of several international
initiatives and projects in the field of
personalised medicine, as well as more than 15
years of successful collaboration among many of
the partners involved. Over the next ten years
(2023-2033), most of EP PerMed’s budget will be
available for funding of research projects and the
implementation of personalised medicine
approaches.
The 1st
EP PerMed call aims to fund research for the
identification or validation of targets for
personalised medicine approaches. Applicants must
combine the research on new and advanced targets
with companion biomarker research. The call will
be launched early in January 2024 and will be
based on the Strategic
Research and Innovation Agenda for Personalised
Medicine (SRIA PerMed).
Also, on the basis of the SRIA, additional EP
PerMed activities will focus on actions to support
and accelerate innovations in personalised
medicine and its uptake into healthcare systems.
These activities include, for example, partnering
events between the research communities and the
private sector, calls for personalised medicine
pilots, particularly in a regional context, and
surveys to identify and contact key players in the
healthcare systems and medical societies.
All steps of the SRIA development and the
proposal preparation were strongly supported by
numerous PM-experts, stakeholders and the European
Commission (EC). The partnership builds on several
initiatives, projects and activities such as ERA
PerMed, ICPerMed and
its supporting projects (ICPerMed
'Family'). ICPerMed will further support and
collaborate with EP PerMed for example as part of
the Extended General Assembly (ExtGeA) of this
partnership.
Further information: www.eppermed.eu
EP PerMed contact: DLR Project Management
Agency (Coordination EP PerMed), eppermed@dlr.de
|